03933.HK
The United Laboratories International Holdings Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 7.92
+1.67%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenHKD 7.76
From 52W high−53.66%
Volume10.53M
Market capHKD 23.73B
P/E (TTM)24.4x
P/S (TTM)1.7x
Div yield5.99%
Key dataSep 18, 2026
Open
HKD 7.76
From 52W high
−53.66%
Volume
10.53M
Market cap
HKD 23.73B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
11.7x
P/E (TTM)
24.4x
RSI (14)
37.8
MomentumView details →
1D Return
+1.67%
YTD Return
−31.67%
Similar companies
Latest newsMore news →
United Laboratories' subsidiary United Biotechnology completed the first dosing in a Phase III clinical trial in China for its innovative drug UBT251 injection for type 2 diabetes.13d agoUnited Laboratories' subsidiary United Biotechnology completed the first dosing of its investigational drug UBT251 in a Phase III clinical trial for overweight/obesity in China.14d agoUnited Laboratories International Holdings Limited reported interim results for the six months ended June 2026, with revenue of RMB 6.166 billion, down 18% year-on-year, and net profit of RMB 348 million, down 81.6% year-on-year.20d ago